Additional file 6: Figure S6. of An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia HerZhisheng YongKylie ParamasivamKathirvel TanWilson ChanXue TanSue LiuMin FanYong LinnYeh HuiKam SuranaUttam ChenQingfeng 2017 Sorafenib and Regorafenib treatment has no impact on the frequency of CD34+ and CD34+CD117+ AML cells in mice. Magnetically sorted CD34+ pooled BM cells and splenocytes from secondary-engrafted NSG mice were injected intrahepatically in newborn NSG pups after sublethal irradiation (1 × 105 cells per pup). Successfully engrafted mice with more than 30 human CD45+ cells per microliter of blood (between week 12 to 16 post-engraftment) were randomly assigned to either untreated (n = 3), Regorafenib (n = 6; 5 mg/kg body weight; gavage-fed once daily), or Sorafenib (n = 6; 10 mg/kg body weight; gavage-fed once daily) treatment groups and monitored for 1 month. a Representative flow cytometry plots illustrating the expression of CD34 and CD117 in human CD45 cells. b Comparison of the frequencies of total CD34+ (B, above) and CD34+CD117+ (B, below) cells relative to human CD45 cells in peripheral blood, spleen, and BM of different treatment groups after 4 weeks post-drug treatment. Data are presented as mean frequencies ± SEM. (TIFF 1403 kb)